BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) insider Xiaodong Wang sold 41,760 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $186.90, for a total transaction of $7,804,944.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Xiaodong Wang also recently made the following trade(s):
- On Tuesday, November 26th, Xiaodong Wang sold 40,468 shares of BeiGene stock. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80.
BeiGene Stock Performance
Shares of BGNE stock opened at $180.27 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $208.56 and a two-hundred day simple moving average of $186.47. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $248.16. The firm has a market capitalization of $17.56 billion, a PE ratio of -21.88 and a beta of 0.57.
This Crypto Is Set to Explode in December
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
BeiGene (NASDAQ:BGNE - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. During the same quarter in the previous year, the company posted $2.01 EPS. The business's quarterly revenue was up 28.2% on a year-over-year basis. Analysts forecast that BeiGene, Ltd. will post -5.64 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms recently commented on BGNE. Morgan Stanley reiterated an "overweight" rating and set a $300.00 target price on shares of BeiGene in a research report on Tuesday, December 3rd. JMP Securities began coverage on shares of BeiGene in a research report on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 22nd. TD Cowen raised their price target on shares of BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Finally, StockNews.com lowered shares of BeiGene from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $253.69.
Read Our Latest Research Report on BeiGene
Institutional Trading of BeiGene
Several institutional investors have recently made changes to their positions in the company. Blue Trust Inc. grew its stake in shares of BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock worth $28,000 after acquiring an additional 75 shares in the last quarter. Raymond James & Associates lifted its holdings in BeiGene by 0.4% during the second quarter. Raymond James & Associates now owns 21,275 shares of the company's stock valued at $3,035,000 after purchasing an additional 76 shares during the last quarter. Truist Financial Corp lifted its holdings in BeiGene by 10.1% during the second quarter. Truist Financial Corp now owns 1,521 shares of the company's stock valued at $217,000 after purchasing an additional 140 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in BeiGene during the third quarter valued at about $36,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in BeiGene by 0.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company's stock valued at $21,978,000 after purchasing an additional 266 shares during the last quarter. Institutional investors own 48.55% of the company's stock.
BeiGene Company Profile
(
Get Free Report)
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
